View Item 

Show simple item record

The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference *
dc.contributor.authorHatzakis, A.en_US
dc.contributor.authorWait, S.en_US
dc.contributor.authorBruix, J.en_US
dc.contributor.authorButi, M.en_US
dc.contributor.authorCarballo, M.en_US
dc.contributor.authorCavaleri, M.en_US
dc.contributor.authorColombo, M.en_US
dc.contributor.authorDelarocque‐astagneau, E.en_US
dc.contributor.authorDusheiko, G.en_US
dc.contributor.authorEsmat, G.en_US
dc.contributor.authorEsteban, R.en_US
dc.contributor.authorGoldberg, D.en_US
dc.contributor.authorGore, C.en_US
dc.contributor.authorLok, Anna Suk-Fongen_US
dc.contributor.authorManns, M.en_US
dc.contributor.authorMarcellin, P.en_US
dc.contributor.authorPapatheodoridis, G.en_US
dc.contributor.authorPeterle, A.en_US
dc.contributor.authorPrati, D.en_US
dc.contributor.authorPiorkowsky, N.en_US
dc.contributor.authorRizzetto, M.en_US
dc.contributor.authorRoudot‐thoraval, F.en_US
dc.contributor.authorSoriano, Vincenten_US
dc.contributor.authorThomas, H. C.en_US
dc.contributor.authorThursz, M.en_US
dc.contributor.authorValla, D.en_US
dc.contributor.authorvan Damme, P.en_US
dc.contributor.authorVeldhuijzen, I. K.en_US
dc.contributor.authorWedemeyer, H.en_US
dc.contributor.authorWiessing, L.en_US
dc.contributor.authorZanetti, A. R.en_US
dc.contributor.authorJanssen, H. L. A.en_US
dc.date.accessioned2011-11-10T15:40:20Z
dc.date.available2012-11-02T18:56:56Zen_US
dc.date.issued2011-09en_US
dc.identifier.citationHatzakis, A.; Wait, S.; Bruix, J.; Buti, M.; Carballo, M.; Cavaleri, M.; Colombo, M.; Delarocque‐astagneau, E. ; Dusheiko, G.; Esmat, G.; Esteban, R.; Goldberg, D.; Gore, C.; Lok, A. S. F.; Manns, M.; Marcellin, P.; Papatheodoridis, G.; Peterle, A.; Prati, D.; Piorkowsky, N.; Rizzetto, M.; Roudot‐thoraval, F. ; Soriano, V.; Thomas, H. C.; Thursz, M.; Valla, D.; van Damme, P.; Veldhuijzen, I. K.; Wedemeyer, H.; Wiessing, L.; Zanetti, A. R.; Janssen, H. L. A. (2011). "The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference * ." Journal of Viral Hepatitis 18. <http://hdl.handle.net/2027.42/87185>en_US
dc.identifier.issn1352-0504en_US
dc.identifier.issn1365-2893en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/87185
dc.publisherBlackwell Publishing Ltden_US
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherEuropeen_US
dc.subject.otherHepatitis Ben_US
dc.subject.otherHepatitis Cen_US
dc.subject.otherLiver Canceren_US
dc.subject.otherPolicyen_US
dc.titleThe state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference *en_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDivision of Gastroenterology and Hepatology, University of Michigan Health System, Ann Arbor, MI, USAen_US
dc.contributor.affiliationotherDepartment of Hygiene, Epidemiology and Medical Statistics, Athens University Medical School, Athens, Greeceen_US
dc.contributor.affiliationotherSHW Health Ltd, London, UKen_US
dc.contributor.affiliationotherBCLC Group, Liver Unit, CIBEREHD, IDIBAPS, Hospital Clinic, University of Barcelonaen_US
dc.contributor.affiliationotherLiver Unit, Hospital Universitari Valle Hebron and CIBEREH del Instituto Carlos III, Barcelona, Spainen_US
dc.contributor.affiliationotherInternational Centre for Migration and Health, Geneva, Switzerlanden_US
dc.contributor.affiliationotherAnti‐Infectives and Vaccines, Safety and Efficacy of Medicines, European Medicines Agency (EMA), London, UKen_US
dc.contributor.affiliationother1st Division of Gastroenterology, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, Italyen_US
dc.contributor.affiliationotherInstitut National de Veille Sanitaire and Emerging Diseases Epidemiology Unit, Institut Pasteur, Paris, Franceen_US
dc.contributor.affiliationotherCentre for Hepatology, Royal Free Hospital, London, UKen_US
dc.contributor.affiliationotherFaculty of Medicine, Department of Tropical Medicine and Hepatology, Cairo University, Cairo, Egypten_US
dc.contributor.affiliationotherHealth Protection Scotland, Glasgow, Scotlanden_US
dc.contributor.affiliationotherWorld Hepatitis Alliance, London, UKen_US
dc.contributor.affiliationotherDepartment of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germanyen_US
dc.contributor.affiliationotherDepartment of Hepatology and INSERM U773‐CRB3 (Centre de Recherche Biomédicale Bichat‐Beaujon), Clichy, Franceen_US
dc.contributor.affiliationother2nd Department of Internal Medicine, Athens University Medical School, Hippokration General Hospital of Athens, Athens, Greeceen_US
dc.contributor.affiliationotherMember of the European Parliament, Brussels, Belgiumen_US
dc.contributor.affiliationotherDepartment of Transfusion Medicine and Hematology, Ospedale “Alessandro Manzoni”, Lecco and Centre of Transfusion Medicine, Cellular Therapy and Cryobiology, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italyen_US
dc.contributor.affiliationotherEuropean Liver Patients Association, Sint Truiden, Belgiumen_US
dc.contributor.affiliationotherDivision of Gastroenterology, University of Torino, Torino, Italyen_US
dc.contributor.affiliationotherInfectious Diseases Department, Hospital Carlos III, Madrid, Spainen_US
dc.contributor.affiliationotherDepartment of Hepatology and Gastroenterology, Imperial College, London, UKen_US
dc.contributor.affiliationotherDepartment of Hepatology and Gastroenterology, Imperial College, London and Secretary‐General of the European Association for Study of the Liver (EASL), London, UKen_US
dc.contributor.affiliationotherService d’hépatologie, Hôpital Beaujon, APHP, Université Paris‐Diderot, and INSERM CRB3, Paris, Franceen_US
dc.contributor.affiliationotherFaculty of Medicine, Centre for the Evaluation of Vaccination, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgiumen_US
dc.contributor.affiliationotherMunicipal Public Health Service Rotterdam‐Rijnmond, Division of Infectious Disease Control, Rotterdam, The Netherlandsen_US
dc.contributor.affiliationotherDepartment of Gastroenterology, Hepatology and Endocrinology, University of Hannover, Hannover, Germanyen_US
dc.contributor.affiliationotherEuropean Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Lisbon, Portugalen_US
dc.contributor.affiliationotherDepartment of Public Health – Microbiology – Virology, University of Milan, Milan, Italyen_US
dc.contributor.affiliationotherErasmus MC University Medical Center Rotterdam, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlandsen_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/87185/1/j.1365-2893.2011.01499.x.pdf
dc.identifier.doi10.1111/j.1365-2893.2011.01499.xen_US
dc.identifier.sourceJournal of Viral Hepatitisen_US
dc.identifier.citedreferenceWiersma S. The global burden of disease of viral hepatitis. Viral Hepat 2011; 19: 9 – 10.en_US
dc.identifier.citedreferenceKleinman SH, Lelie N, Busch MP. Infectivity of human immunodeficiency virus‐1, hepatitis C virus and hepatitis B virus and risk of transmission by transfusion. Transfusion 2009; 49: 2454 – 2489.en_US
dc.identifier.citedreferenceWHO. Hepatitis B fact sheet no. 204, 2009. Available at: http://www.who.int/mediacentre/factsheets/fs204/en/. (Accessed on 12 July 2011).en_US
dc.identifier.citedreferenceEuropean Liver Patients Association (ELPA). Report on hepatitis patient self‐help in Europe. Available at: http://www.hepsummit2010.org (Accessed on 11 July 2011).en_US
dc.identifier.citedreferenceInstitute of Medicine. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C. Washington, DC: The National Academies Press, 2010.en_US
dc.identifier.citedreferenceEuropean Centre for Disease Prevention and Control (ECDC). Surveillance and prevention of hepatitis B and C in Europe. ECDC technical report, Stockholm, October 2010.en_US
dc.identifier.citedreferenceEuropean Centre for Disease Prevention and Control (ECDC). Hepatitis B and C in the EU neighbourhood: prevalence, burden of disease and screening policies. ECDC technical report, Stockholm, September 2010.en_US
dc.identifier.citedreferenceFattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48 ( 2 ): 335 – 352.en_US
dc.identifier.citedreferenceFattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127 ( 5 Suppl. 1 ): S35 – S50.en_US
dc.identifier.citedreferenceIloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Risk evaluation of viral load elevation and associated liver disease/cancer‐In HBV (the REVEAL‐HBV) study group. Gastroenterology 2006; 130 ( 3 ): 678 – 686.en_US
dc.identifier.citedreferenceChen C‐J, Yang H, Su J et al., for the REVEAL‐HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295 ( 1 ): 65 – 73.en_US
dc.identifier.citedreferenceSeeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36: 535 – 546.en_US
dc.identifier.citedreferenceMissiha SB, Ostrowski M, Heathcote EJ. Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors. Gastroenterology 2008; 134 ( 6 ): 1699 – 1714.en_US
dc.identifier.citedreferenceMcDonald SA, Hutchinson SJ, Bird SM et al. Excess morbidity in the hepatitis C‐diagnosed population in Scotland, 1991–2006. Epidemiol Infect 2011; 139: 344 – 353.en_US
dc.identifier.citedreferenceRibes J, Clèries R, Esteban L, Moreno V, Bosch FX. The influence of alcohol consumption and hepatitis B and C infections on the risk of liver cancer in Europe. J Hepatol 2008; 49 ( 2 ): 233 – 242.en_US
dc.identifier.citedreferenceBosetti C, Levi F, Boffetta P, Lucchini F, Negri E, La Vecchia C. Trends in mortality from hepatocellular carcinoma, 1980–2004. Hepatology 2008; 48 ( 1 ): 137 – 145.en_US
dc.identifier.citedreferenceLlovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907 – 1917.en_US
dc.identifier.citedreferenceDegos F, Christidis C, Ganne‐Carrie N et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut 2000; 47 ( 1 ): 131 – 136.en_US
dc.identifier.citedreferenceSangiovanni A, Prati GM, Fasani P et al. The natural history of compensated cirrhosis due to hepatitis C virus: a 17‐year cohort study of 217 patients. Hepatology 2006; 43 ( 6 ): 1303 – 1310.en_US
dc.identifier.citedreferenceChang M‐H, You S‐L, Chen C‐J et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccines: a 20‐year follow‐up study. J Natl Cancer Inst 2009; 101: 1348 – 1355.en_US
dc.identifier.citedreferenceZanetti A, van Damme P, Shouval D. The global impact of vaccination against hepatitis B. A historical overview. Vaccine 2008; 26: 6266 – 6273.en_US
dc.identifier.citedreferenceHernàn MA, Jick SS, Olek MJ, Jick H. Recombinant hepatitis B vaccine and the risk of multiple sclerosis. A prospective study. Neurology 2004; 63: 838 – 842.en_US
dc.identifier.citedreferenceMikaeloff Y, Caridade G, Suissa S et al. Hepatitis B vaccine and the risk of CNS inflammatory demyelination in childhood. Neurology 2009; 72: 873 – 880.en_US
dc.identifier.citedreferenceWorld Health Organization global advisory committee on vaccine safety: Response to the paper by MA Hernan and others in Neurology 14th September 2004 issue entitled “Recombinant hepatitis B vaccine and the risk of multiple sclerosis”. Available at: http://www.who.int/vaccine_safety/topics/hepatitisb/multiple_sclerosis/sep_04/en/ (Accessed 11 July 2011).en_US
dc.identifier.citedreferenceZanetti AR, Mariano A, Romanò L et al. Long‐term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet 2005; 366: 1379 – 1384.en_US
dc.identifier.citedreferenceWest DJ, Calandra GB. Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. Vaccine 1996; 14: 1019 – 1027.en_US
dc.identifier.citedreferenceBanatvala JE, Van Damme P. Hepatitis B vaccine: do we need boosters? J Hepatol 2003; 10: 1 – 6.en_US
dc.identifier.citedreferenceEuropean Consensus on Hepatitis B Immunity. Are booster immunisations needed for lifelong hepatitis B immunity? Lancet 2000; 355: 561 – 565.en_US
dc.identifier.citedreferenceKao J‐H, Chen DS. Hepatitis B vaccination: to boost or not to boost? Lancet 2005; 366: 1337 – 1338.en_US
dc.identifier.citedreferenceHutton DW, Tan D, So SK, Brandeau ML. Cost‐effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B. Ann Intern Med 2007; 147: 460 – 469.en_US
dc.identifier.citedreferenceVeldhuijzen IK, Toy M, Hahne SJ et al. Screening and early treatment of migrants for chronic hepatitis B virus infection is cost‐effective. Gastroenterology 2010; 138 ( 2 ): 522 – 530.en_US
dc.identifier.citedreferenceSroczynski G, Esteban E, Conrads‐Frank A et al. Long term effectiveness of screening for hepatitis C virus infection. Eur J Pub Health 2009; 19: 245 – 253.en_US
dc.identifier.citedreferenceViral hepatitis prevention Board. Identification and management of persons with chronic viral hepatitis in Europe, Budapest, March 2010. Viral Hepat 2011; 1 ( 19 ): 1 – 40. Available at: http://www.vhpb.org.en_US
dc.identifier.citedreferenceJanssen HLA, van Zonneveld M, Senturk H et al., for the HBV 99‐01 Study Group. Pegylated interferon alfa‐2b alone or in combination with lamivudine for HBeAg‐positive chronic hepatitis B: a randomised trial. Lancet 2005; 365: 123 – 129.en_US
dc.identifier.citedreferencede Vries–Sluijs TEMS, Reijnders JGP, Hansen BE et al. Long‐term therapy with tenofovir is effective for patients co‐infected with human immunodeficiency virus and hepatitis B virus. Gastroenterology 2010; 139 ( 6 ): 1934 – 1941.en_US
dc.identifier.citedreferenceChang T‐T, Lai C‐L, Yoon SK et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen–positive chronic hepatitis B. Hepatology 2010; 51 ( 2 ): 422 – 430.en_US
dc.identifier.citedreferenceVeldt BJ, Heathcote EJ, Wedemeyer H et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007; 147: 677 – 684.en_US
dc.identifier.citedreferenceButi M, Brosa M, Casado MA, Rueda MA, Esteban R. Modeling the cost‐effectiveness of different oral antiviral therapies in patients with chronic hepatitis B. J Hepatol 2009; 51: 640 – 646.en_US
dc.identifier.citedreferenceEuropean Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245 – 64.en_US
dc.identifier.citedreferenceEuropean Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009; 50 ( 2 ): 227 – 242.en_US
dc.identifier.citedreferenceRausch A, Kutalik Z, Descombes P et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure – a genome‐wide association study. Gastroenterology 2010; 138: 1338 – 45;e7.en_US
dc.identifier.citedreferenceMallet V, Gilgenkrantz H, Serpaggi J et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med 2008; 149: 399 – 403.en_US
dc.identifier.citedreferenceForner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 2010; 30 ( 1 ): 61 – 74.en_US
dc.identifier.citedreferenceBruix J, Sherman M. Management of hepatocellular carcinoma: an update. AADSL update. Hepatology 2011; 53: 1020 – 1022.en_US
dc.identifier.citedreferenceBruix J, Sherman M, Llovet JM et al. EASL panel of experts on HCC. J Hepatol 2001; 35 ( 3 ): 421 – 430.en_US
dc.identifier.citedreferenceCarballo M, Cody R, O’Reilly E. International centre for migration, health and development. Migration, hepatitis B and C, September 2010. Available at: http://www.hepsummit2010.org.en_US
dc.identifier.citedreferenceMarschall T, Krämer A, Prüfer‐Krämer L, Mikolajczyk R, Kretzschmar M. Does migration from high and intermediate endemic regions increase the prevalence of hepatitis B infection in Germany? Dtsch Med Wochenschr 2005; 130 ( 48 ): 2753 – 2758. [Article in German].en_US
dc.identifier.citedreferenceRechel B, Blackburn CM, Spencer NJ, Rechel B. Access to health care for Roma children in Central and Eastern Europe: findings from a qualitative study in Bulgaria. Int J Equity Health 2009; 8: 24.en_US
dc.identifier.citedreferenceCarballo M. The process of social insertion of migrants, refugees and asylum seekers in the context of access to and use of health and social services. Synthesis and recommendations. ICMH/Synthese Geneva report 2004.en_US
dc.identifier.citedreferenceWiessing L, Guarita B, Giraudon H, Brummer‐Korvenkontio H, Salminen M, Cowan SA. European monitoring of notifications of hepatitis C virus infection in the general population and among injecting drug users (IDUs) – the need to improve quality and comparability. Eurosurveillance 2008; 13 ( 21 ): 1 – 5.en_US
dc.identifier.citedreferenceHagan H, Snyder N, Hough E et al. Case‐reporting of acute hepatitis B and C among injection drug users. J Urban Health 2002; 79: 579 – 585.en_US
dc.identifier.citedreferenceWiessing L, Blystad H. EMCDDA publishes guidelines on testing for HIV, viral hepatitis and other infections in injecting drug users. Euro Surveill 2010; 15 ( 48 ): pii=19735. Available at: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19735 (Accessed 11 July 2011)en_US
dc.identifier.citedreferenceMartin NK, Vickerman P, Foster GR, Hutchinson SJ, Goldberg DJ, Hickman M. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J Hepatol 2011; 54 ( 6 ): 1137 – 44.en_US
dc.identifier.citedreferenceMontaner JS, Lima VD, Barrios R et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population‐based study. Lancet 2010; 376 ( 9740 ): 532 – 539.en_US
dc.identifier.citedreferenceHellard M, Sacks‐Davis R, Gold J. Hepatitis C treatment for injecting drug users: a review of available evidence. Clin Infect Dis 2009; 49 ( 4 ): 561 – 573..en_US
dc.identifier.citedreferenceDalgard O. Follow up studies of treatment for hepatitis C virus infection among injecting drug users. Clin Infect Dis 2005; 40 ( s5 ): S336 – S338.en_US
dc.identifier.citedreferenceEMA. Guideline: clinical evaluation of medicinal products intended for treatment of hepatitis B, 2006. adopted February 2006.en_US
dc.identifier.citedreferenceEMA. Guideline: clinical evaluation of direct acting antiviral agents intended for treatment of chronic hepatitis C, 2009. adopted May 2009.en_US
dc.identifier.citedreferenceDelarocque‐Astagneau E, Meffre C, Dubois F et al., Hepatitis C Surveillance System Committee; Scientific Committee for the National Prevalence Survey of Hepatitis B and C Markers. Hepatitis C Surveillance System Committee; Scientific Committee for the National Prevalence Survey of Hepatitis B and C Markers. The impact of the prevention programme of hepatitis C over more than a decade: the French experience. J Viral Hepat 2010; 17 ( 6 ): 435 – 443.en_US
dc.identifier.citedreferenceLettmeir B, Mühlberger N, Schwarzer R et al. Market uptake of new antiviral drugs for the treatment of hepatitis C. J Hepatol 2008; 49: 528 – 535.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1365-2893.2011.01499.x.pdf
Size:
232.8KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.